IntroductionStrategiesWorkflowWhat We Can OfferHighlightsCustomer ReviewsFAQsExtended Services
Introduction of WRN & MSS & MSI Cell Panel Screening Service
Werner Syndrome RecQ Helicase (WRN), Microsatellite Stable (MSS), and Microsatellite Instability (MSI) represent crucial genomic and molecular markers with profound implications in cancer biology and therapeutic response. WRN plays a vital role in DNA repair and genomic stability; its dysfunction can lead to genomic instability and altered drug sensitivity. MSI, particularly high MSI (MSI-H), results from defective mismatch repair (MMR) and is a well-established biomarker predicting favorable responses to immune checkpoint inhibitors in various solid tumors. Conversely, MSS tumors often exhibit different biological characteristics and therapeutic vulnerabilities. Our comprehensive cell panel screening service leverages these distinct profiles, offering a powerful platform to identify compounds that differentially impact cells based on their WRN status, MSS, or MSI phenotype. This targeted approach is essential for advancing precision oncology, as supported by published research demonstrating the clinical relevance of these biomarkers in predicting treatment outcomes and guiding therapeutic strategies.
Creative Biolabs' WRN & MSS & MSI cell panel screening service provides precise and actionable insights into the efficacy and selectivity of your compounds against diverse cancer cell lines characterized by their specific WRN, MSS, or MSI status. We deliver comprehensive data on compound potency, differential sensitivity, and potential mechanisms of action, enabling you to accelerate lead optimization and biomarker discovery. Our service provides robust preclinical evidence, guiding informed decisions in your drug development pipeline.
Strategies
Creative Biolabs employs a multifaceted strategic approach for WRN & MSS & MSI Cell Panel Screening to ensure comprehensive and biologically relevant data. Our strategies focus on:
Genomic Contextualization: Utilizing cell lines with verified genomic status (WRN mutations/deficiencies, specific MSI/MSS status) to precisely identify compounds that exploit vulnerabilities or exhibit selective toxicity based on these genetic backgrounds. This includes using CRISPR-engineered cell lines where relevant to precisely control WRN expression.
Phenotypic Profiling: Beyond simple cytotoxicity, we design assays to assess key cellular phenotypes such as proliferation, cell cycle progression, apoptosis, DNA damage response, and immune modulation (especially for MSI-H lines). This provides a deeper understanding of compound mechanisms.
High-Throughput and High-Content Integration: Combining the efficiency of high-throughput screening with the rich data capture of high-content analysis. This allows for rapid initial screening followed by detailed characterization of promising hits, including subcellular localization and specific protein markers.
Bioinformatics-Driven Analysis: Employing advanced bioinformatics tools to analyze complex datasets, identify correlations between genomic profiles and drug sensitivity, and predict potential biomarkers for patient stratification. This includes pathway analysis to elucidate mechanisms of action.
Combinatorial Screening: Offering the option for combinatorial drug screening to identify synergistic or additive effects of compounds, particularly relevant for overcoming resistance or enhancing efficacy in specific genetic contexts.
Workflow
1. Cell Panel Selection & Characterization
We meticulously select and characterize a diverse panel of human cancer cell lines, including those with defined WRN expression/mutation status, and validated MSS or MSI profiles (MSI-H and MSI-L/MSS). Each cell line undergoes rigorous quality control to ensure authenticity and biological relevance.
2. Assay Design & Optimization
Customized assays are designed to evaluate compound effects, including cell proliferation, viability, apoptosis, DNA damage response, or target engagement. Assays are optimized for sensitivity, robustness, and high-throughput compatibility.
3. High-Throughput Compound Screening
Your compounds are systematically screened across the selected cell panel using automated liquid handling systems and high-content imaging or plate reader technologies. Each compound is tested across a range of concentrations to generate dose-response curves.
4. Data Analysis & Interpretation
Raw data undergoes comprehensive bioinformatics analysis, including dose-response curve fitting, calculation of IC50 values, selectivity indices, and hierarchical clustering to identify patterns of activity. Statistical methods are applied to ensure data reliability.
5. Detailed Report Generation & Consultation
A comprehensive report is provided, summarizing methodology, raw and analyzed data, key findings, and biological interpretations. Our expert scientists are available for consultation to discuss results and strategize next steps.
Required Starting Materials:
Compound Libraries: Your test compounds (e.g., small molecules, antibodies, biologics) in sufficient quantities and specified concentrations.
Targeted Information: Any available preliminary data or hypotheses regarding the compounds' potential mechanisms of action or specific targets.
Project Objectives: Clear definition of desired outcomes, such as identifying selective inhibitors for MSI-H cells or compounds that target WRN-deficient pathways.
What We Can Offer
Creative Biolabs offers a comprehensive suite of services under our WRN & MSS & MSI cell panel screening platform designed to accelerate your oncology research:
Custom Cell Panel Development: Creation of bespoke cell line panels tailored to your specific research interests, including patient-derived cell lines or genetically engineered models.
High-Throughput Screening Services: Efficient and robust screening of small molecule libraries, biologics, and natural products against defined cell panels.
Phenotypic & Pathway-Specific Assays: Implementation of a wide array of cellular assays to measure proliferation, viability, apoptosis, cell cycle, DNA repair pathway activation, and other critical biological processes.
Biomarker Discovery Support: Identification of molecular markers that correlate with drug sensitivity or resistance, aiding precision medicine strategies.
Mechanism of Action Studies: Follow-up studies to elucidate the precise molecular targets and pathways affected by your compounds, including gene expression analysis, proteomics, and target validation.
Highlights
Extensive Cell Line Collection
Access to a vast, meticulously characterized library of cancer cell lines, including those specifically validated for WRN status, MSI-H, MSI-L, and MSS phenotypes, ensuring high relevance to your research.
Advanced Screening Technologies
Utilization of cutting-edge high-throughput screening platforms, automated liquid handling systems, and high-content imaging, enabling rapid, accurate, and cost-effective compound evaluation.
Customization and Flexibility
Our services are highly customizable, adapting to your unique project requirements, from specific assay development to bespoke cell panel selection.
Integrated Solutions
We offer a seamless continuum of services, from initial screening to downstream mechanism-of-action studies and biomarker discovery, providing a holistic research partnership.
Customer Reviews
[Enhanced Drug Selectivity] Using Creative Biolabs' WRN & MSS & MSI Cell Panel Screening Service in our research has significantly improved our ability to identify compounds with selective toxicity towards MSI-H colorectal cancer cells, differentiating them from MSS lines. This allowed us to quickly narrow down our lead candidates. - June 2024, Dr. A*** M***
[Streamlined Lead Optimization] Creative Biolabs' expertise in WRN deficiency screening was instrumental. Their service provided critical insights into how our novel topoisomerase inhibitor impacted WRN-deficient cells, directly guiding our lead optimization efforts and accelerating our preclinical development timeline. - May 2025, Prof. J** P****
[Robust Biomarker Identification] The comprehensive data from Creative Biolabs' MSI/MSS panel screening helped us identify potential biomarkers predicting sensitivity to our novel targeted therapy. The detailed report and follow-up consultation were invaluable for our precision medicine program. - April 2025, Dr. S*** L*****
FAQs
What specific cell lines are included in the WRN & MSS & MSI cell panel?
We utilize a diverse panel of well-characterized cancer cell lines with confirmed WRN expression/mutation status, and validated MSI-H, MSI-L, and MSS profiles. For a detailed list tailored to your project, please contact us for a consultation.
How is the MSI/MSS status of the cell lines confirmed?
The MSI/MSS status is rigorously confirmed using molecular methods such as PCR-based analysis of microsatellite markers and Next-Generation Sequencing (NGS) of mismatch repair genes, ensuring accurate classification.
Can I provide my own custom cell lines for screening?
Yes, we welcome clients to provide their own cell lines. Our team will perform a thorough characterization to integrate them into our screening workflow, ensuring compatibility and data quality.
What types of compounds can be screened using this service?
Our service is versatile and can screen a wide range of compounds, including small molecules, biologics, antibodies, and natural product extracts.
Extended Services
Creative Biolabs offers a suite of complementary services designed to provide comprehensive support for your oncology drug discovery programs, extending beyond the core WRN & MSS & MSI Cell Panel Screening.
In VitroADME Screening: Evaluate the Absorption, Distribution, Metabolism, Excretion, and Toxicology profiles of your compounds early in the discovery process.
Mechanism of Action (MoA) Studies: Delve deeper into how your compounds exert their effects, using advanced molecular and cellular biology techniques.
Target Validation Services: Confirm the specific molecular targets of your drug candidates and their functional relevance.
In Vivo Efficacy Studies: Transition from in vitro to in vivo models to assess compound efficacy in relevant animal models of cancer.
Biomarker Discovery & Development: Identify and validate predictive or prognostic biomarkers to enhance patient stratification and guide clinical trials.
Creative Biolabs is committed to accelerating your oncology drug discovery efforts with our expert WRN & MSS & MSI Cell Panel Screening Service. Our dedicated team is ready to provide tailored solutions and insightful support at every stage of your project.
Contact Our Team for More Information and to Discuss Your Project today and take the next step in advancing precision oncology.
